Multiple Sclerosis: Diagnosis, Treatment and Living With It
Multiple sclerosis has changed more in the last thirty years than almost any neurological condition. It remains incurable, and the phrase that used to accompany that — that nothing much can be done — has stopped being true. There are now around twenty medications that reduce relapses and slow the accumulation of disability, and the direction of practice has shifted decisively toward using them early.
Anyone reading older material describing MS as managed with physiotherapy and muscle relaxants is reading a description of treatment from before that happened.
🧠 The change that matters most: damage in MS accumulates from the beginning, including during periods when someone feels entirely well, and much of it is not reversible. That is why the approach has moved from waiting to see how the disease behaves before treating, toward starting effective disease-modifying treatment early. Relapses are the visible part; the underlying process runs continuously beneath them.
🧠 What is happening
Nerve fibres in the brain and spinal cord are wrapped in myelin, a fatty insulating sheath that allows electrical signals to travel quickly and reliably. In MS the immune system attacks that myelin, producing patches of inflammation and damage — the plaques or lesions seen on scans.
Signals through a damaged segment slow, distort or fail entirely, and the symptom produced depends purely on which pathway is affected. That is why MS can present as blurred vision in one eye, or numbness in a hand, or a heavy leg, or double vision, or unsteadiness, with no single characteristic picture.
Early on, inflammation settles and some myelin repairs, which is why early symptoms often improve or resolve completely. Over time, repair becomes less effective and the underlying nerve fibres themselves are lost, which is what produces permanent disability. That transition from an inflammatory to a degenerative process is the central problem in MS and the reason early intervention matters.
🗂️ The patterns
| Type | Course |
|---|---|
| Clinically isolated syndrome | A first episode of neurological symptoms consistent with MS. Whether it becomes MS depends largely on what the MRI shows |
| Relapsing remitting | The commonest form at diagnosis, around eight in ten. Episodes of new or worsening symptoms lasting days to weeks, with recovery between — complete at first, less so later |
| Secondary progressive | Gradual accumulation of disability developing after years of relapsing disease, with or without continuing relapses |
| Primary progressive | Gradual worsening from the outset without distinct relapses. Around one in ten, with later onset and a more equal sex distribution |
| Radiologically isolated syndrome | Typical lesions found incidentally on a scan done for another reason, with no symptoms. Some go on to develop MS; monitoring rather than treatment is usual |
Two points about this classification. The proportion progressing to secondary progressive disease has fallen since effective treatment became available, which is one of the clearest signs that treatment changes the course. And the distinction between relapsing and progressive forms is less absolute than it appears — the underlying degenerative process is present throughout, and the labels describe what is visible rather than what is happening.
👁️ Symptoms
The commonest presenting features are the ones that involve a discrete pathway.
Optic neuritis — blurred or lost vision in one eye developing over hours to days, with pain on moving the eye and reduced colour perception, particularly of red. It usually recovers substantially.
Sensory disturbance — numbness, tingling, a band-like tightness around the trunk, or an electric-shock sensation running down the spine when the neck is bent forward.
Weakness, typically of a limb, and often described as heaviness or dragging rather than obvious weakness.
Double vision or unsteadiness from brainstem involvement.
Beyond the presenting features, the symptoms that dominate daily life are frequently different and less visible:
| Symptom | Note |
|---|---|
| Fatigue | Affects the great majority and is consistently rated the most disabling symptom. Qualitatively different from ordinary tiredness and not explained by activity levels |
| Bladder dysfunction | Urgency, frequency, incomplete emptying, night-time waking. Extremely common and under-reported through embarrassment |
| Spasticity | Stiffness and spasms, particularly in the legs, causing pain and disturbed sleep |
| Pain | Nerve pain, trigeminal neuralgia, and pain secondary to spasticity and altered posture |
| Cognitive change | Slowed processing, difficulty with attention and multitasking, word-finding problems. Frequently present early and rarely asked about |
| Depression and anxiety | Considerably commoner than in the general population, partly from the disease process itself |
| Bowel problems | Constipation predominantly |
| Sexual dysfunction | Common in both sexes, rarely raised by either party |
| Heat sensitivity | See below |
🌡️ Two things that look like relapses and are not
Both cause unnecessary alarm and unnecessary treatment, and recognising them saves a great deal of both.
Heat sensitivity. Raising body temperature slows conduction through demyelinated nerve fibres, so symptoms temporarily worsen with a hot bath, hot weather, exercise or a fever. Vision may blur, legs may feel heavier, fatigue may deepen. It resolves within minutes to hours of cooling down, causes no new damage, and is not a relapse. Historically a hot bath was even used as a diagnostic test. Practically it means preferring cooler showers, cooling before and during exercise, and not concluding that exercise is harmful because it temporarily worsens symptoms.
Pseudorelapse. Any infection, most commonly a urinary tract infection, can cause previously resolved symptoms to reappear or existing ones to worsen substantially. This is not new inflammation and it does not respond to steroids — it responds to treating the infection.
⚠️ Any sudden worsening in MS should prompt a check for infection before it is assumed to be a relapse, and a urine test in particular. Bladder dysfunction makes urinary infection common in MS, infections are frequently symptomless in this group apart from the neurological worsening they cause, and treating a pseudorelapse with steroids delays the antibiotic that would have fixed it. Overheating, poor sleep and stress produce the same pattern more mildly.
🧪 How it is diagnosed
Diagnosis requires demonstrating that damage has occurred in more than one place in the central nervous system and at more than one point in time, while excluding other explanations. Those two requirements are called dissemination in space and in time.
MRI is central. Characteristic lesions appear in typical locations, and contrast highlights active inflammation. A significant refinement is that lesions of different ages appearing on a single scan can now satisfy the time requirement, which means MS can sometimes be diagnosed after a first episode rather than requiring a second.
Lumbar puncture examines the spinal fluid for oligoclonal bands — antibody patterns present in the fluid but not the blood, indicating immune activity confined to the nervous system. Present in the large majority with MS, and their presence after a first episode supports the diagnosis.
Evoked potentials measure conduction speed along visual and other pathways and can reveal damage that produced no symptoms.
Blood tests exclude conditions that mimic MS — B12 deficiency, thyroid disease, lupus and other autoimmune conditions, and specific antibody tests for two conditions that resemble MS and are treated quite differently.
🔴 Misdiagnosis is a genuine and well-documented problem in MS, and the commonest reason is over-interpretation of MRI. White matter spots are extremely common in migraine, in small vessel disease with age and blood pressure, and in various other conditions, and they are not MS unless they are in typical locations with typical appearance alongside a compatible clinical picture. People have been treated for MS for years on the basis of a scan report and non-specific symptoms. If a diagnosis rests mainly on white spots without a clear clinical episode, a specialist second opinion is entirely reasonable.
🔬 What causes it
MS results from a combination of genetic susceptibility and environmental exposure, and one environmental factor has become far clearer recently.
Epstein-Barr virus. A large study following millions of young adults found that infection with EBV — the virus causing glandular fever — increased the subsequent risk of MS enormously, and that MS essentially did not occur in people who had never been infected. The current view is that EBV infection appears to be a necessary though far from sufficient condition. Since most of the population is infected and very few develop MS, this is a piece of the mechanism rather than a predictor for any individual, and it is driving research into vaccination and antiviral approaches.
Vitamin D and latitude. MS is markedly commoner further from the equator, and low vitamin D levels and low sun exposure in childhood and adolescence are associated with higher risk.
Smoking increases both the risk of developing MS and the rate at which it progresses, and stopping improves the course.
Obesity in adolescence is associated with increased risk.
Genetics contribute without determining. Having a parent or sibling with MS raises risk several-fold above the general population while still leaving it low in absolute terms, and MS is not inherited in any straightforward way.
💊 Disease-modifying treatment
This is what has changed, and it is the most important section here.
Disease-modifying therapies reduce relapse frequency, reduce new lesion formation and slow the accumulation of disability. They do not repair existing damage and they do not treat symptoms. They are taken continuously, whether or not the person feels well, because their purpose is preventing what has not happened yet.
They range from injectable treatments used since the 1990s with modest effect and good safety records, through oral options, to highly effective infused antibody treatments that suppress relapses almost entirely in many people. The more effective agents carry greater risks — infection, and in some cases specific serious complications requiring monitoring — which is what the choice weighs.
Two developments in how they are used matter more than the individual drugs:
Early treatment. Starting soon after diagnosis produces better long-term outcomes than waiting, because damage accumulates from the outset.
Early high-efficacy treatment. The traditional approach started with a safer, less effective drug and escalated if the disease broke through. Increasing evidence favours starting with a highly effective agent in people with active disease, since disability prevented is disability that never accumulates, and time spent on inadequate treatment is not recoverable. This remains an area of genuine debate, and it is a conversation worth having explicitly rather than accepting a default.
Options are considerably more limited in primary progressive disease, though one treatment has demonstrated benefit and more are in development.
⚡ Treating a relapse
A relapse means new or worsening symptoms lasting more than twenty-four hours, in the absence of infection or overheating, developing over hours to days.
Significant relapses are treated with high-dose corticosteroids for a short course, usually three to five days. Steroids speed recovery from a relapse; they do not change how complete the eventual recovery is, and they do not affect the long-term course. That is why mild relapses are frequently not treated at all — the drawbacks of steroids outweigh a few days of faster recovery in a symptom that will resolve regardless.
Where a relapse is severe and does not respond, plasma exchange is used in some centres.
Rehabilitation after a relapse matters more than is generally appreciated, and physiotherapy input following a significant relapse improves the functional endpoint rather than merely the speed of getting there.
🎯 Managing the symptoms that matter
Disease-modifying treatment does nothing for symptoms, and symptom management is where most of the quality-of-life gain lies.
Fatigue is the most disabling symptom for most people and the most poorly served. What helps: excluding other causes, since anaemia, thyroid disease, sleep apnoea, depression and medication side effects all contribute and are treatable; treating sleep disruption, which is frequently caused by spasticity, spasms or night-time bladder waking; energy management and pacing; and exercise, which counterintuitively reduces fatigue rather than worsening it. Specific medications are sometimes used with modest effect.
Spasticity is managed with stretching, positioning and physiotherapy alongside medication. Baclofen and tizanidine are the usual oral choices, botulinum toxin is used for focal problems, and an intrathecal baclofen pump delivers the drug directly to the spinal cord in severe cases at a fraction of the oral dose, avoiding the sedation that limits tablets. One caution applies throughout: some people rely on increased tone to stand and transfer, and reducing it too far removes a function they were using. This is covered in the guide to muscle spasticity.
Bladder problems deserve more attention than they receive. Assessment should include measuring how much urine remains after voiding, because the treatment for an overactive bladder is the opposite of the treatment for incomplete emptying, and giving the wrong one makes things considerably worse. Where overactivity dominates, anticholinergic medication such as oxybutynin is used; where emptying is incomplete, intermittent self-catheterisation is the answer and is far more manageable than people expect. Treating this well reduces urinary infections, which in turn reduces pseudorelapses.
Pain is neuropathic in character and responds to the drugs used for nerve pain rather than to ordinary analgesics. Trigeminal neuralgia occurs in MS and has specific treatment.
Cognitive difficulty is common, appears early, and is rarely asked about. Formal assessment identifies the specific pattern, and strategies plus external structure help more than attempting to restore the underlying capacity.
Depression is commoner than the disability alone would explain and responds to treatment.
Walking difficulty is helped by physiotherapy, orthoses, and in some people by a specific medication that improves conduction in damaged fibres.
🤰 Pregnancy
MS does not reduce fertility and does not itself cause problems in pregnancy, and the pattern of disease activity is distinctive and worth knowing in advance.
Relapse rate falls during pregnancy, particularly in the third trimester, and then rises in the first months after delivery before returning to baseline. That postpartum window is predictable and can be planned for.
The main consideration is disease-modifying treatment, since some agents must be stopped before conception and others may be continued. Some have a required interval between stopping and conceiving. This needs planning with the neurology team months in advance rather than after a positive test, since stopping certain treatments abruptly can cause rebound disease activity that is worse than before.
Breastfeeding is compatible with several treatment options and may itself be associated with a lower postpartum relapse rate.
🏃 What helps beyond medication
Exercise improves fatigue, strength, walking, mood and quality of life, and the old advice to avoid exertion was wrong. Temporary symptom worsening from raised body temperature is not damage, and cooling strategies allow people to exercise who thought they could not.
Stopping smoking slows progression, which makes it one of the few things within an individual control that affects the disease course rather than the symptoms.
Vitamin D deficiency is corrected as standard, though whether supplementation beyond that alters the course remains unproven.
Heat management — cooling garments, cool showers, air conditioning, planning activity for cooler parts of the day — makes a substantial practical difference in summer.
Treating other conditions matters more than people expect, since anaemia, thyroid disease, sleep apnoea and depression all worsen MS symptoms and are all treatable.
On diet: no specific diet has been shown to alter the course of MS. A generally healthy diet is worth following for the usual reasons, and restrictive regimes marketed as MS treatments have no supporting evidence and can cause nutritional problems.
📈 Outlook
The picture people carry from older accounts is considerably worse than the current reality.
Most people with MS never require a wheelchair. Life expectancy is reduced modestly rather than dramatically. The proportion progressing to secondary progressive disease has fallen since effective treatment became available. And the course is highly variable, which cuts both ways — it means predictions for an individual are unreliable, and it means a diagnosis is not a prognosis.
Factors associated with a better course include younger onset, presentation with sensory or visual symptoms, complete recovery from early relapses, few relapses in the early years, low lesion load on MRI, being female, not smoking, and starting effective treatment early.
✅ The questions worth asking at a review: am I on the most appropriate disease-modifying treatment given my disease activity; has my MRI changed since the last one; has my fatigue been assessed and have other causes been excluded; has my bladder been assessed including how well it empties; has anyone asked about mood and about cognition; and am I under a specialist MS nurse or team rather than being seen episodically. Those six cover most of what determines how the next decade goes.
🚨 When to seek advice
- New or worsening symptoms lasting more than a day — after checking for infection and overheating
- Sudden vision loss or eye pain
- Fever, burning on passing urine or cloudy urine, particularly with neurological worsening
- Difficulty passing urine, or a sense of incomplete emptying
- Swallowing difficulty or choking on food
- New or worsening low mood, or any thoughts of self-harm
- Falls, or increasing difficulty walking
- Planning a pregnancy — well in advance, before stopping any treatment
Medication for MS-related spasticity is stocked in the muscle relaxer category, including Lioresal (baclofen) and Zanaflex (tizanidine), alongside Ditropan (oxybutynin) for bladder overactivity. Disease-modifying treatment is prescribed and monitored by a specialist MS service, and symptom medication works best alongside it rather than instead of it.
❓ Frequently asked questions
Is there treatment beyond managing symptoms?
Yes, and this is what has changed. Around twenty disease-modifying therapies now reduce relapses, reduce new lesion formation and slow the accumulation of disability. They do not repair existing damage or treat symptoms, and they are taken continuously whether or not the person feels well, because their purpose is preventing what has not happened yet. Older material describing MS as managed with physiotherapy alone predates all of it.
Why start treatment when I feel well between relapses?
Because damage accumulates from the beginning, including during periods of feeling entirely well, and much of it is not reversible. Relapses are the visible part of a process running continuously beneath them. Starting soon after diagnosis produces better long-term outcomes than waiting to see how the disease behaves, and time spent on no treatment or inadequate treatment is not recoverable.
Why do my symptoms worsen in hot weather or after a bath?
Raised body temperature slows conduction through demyelinated nerve fibres, so symptoms temporarily worsen with heat, exercise or fever. Vision blurs, legs feel heavier, fatigue deepens. It resolves within minutes to hours of cooling, causes no new damage and is not a relapse. Practically it means cooler showers, cooling before and during exercise, and not concluding that exercise is harmful because it temporarily worsens things.
My old symptoms have come back. Is that a relapse?
Possibly not. Any infection, most commonly urinary, can cause previously resolved symptoms to reappear or existing ones to worsen substantially. This is a pseudorelapse — it is not new inflammation, it does not respond to steroids, and it resolves when the infection is treated. Any sudden worsening should prompt a urine check before being assumed to be a relapse, since treating it with steroids delays the antibiotic that would have fixed it.
I have white spots on my MRI. Does that mean MS?
Not by itself, and over-interpretation of MRI is the commonest cause of MS misdiagnosis. White matter spots are extremely common in migraine, in small vessel disease with age and blood pressure, and in various other conditions. They indicate MS only when in typical locations with typical appearance alongside a compatible clinical picture. A diagnosis resting mainly on white spots without a clear clinical episode warrants a specialist second opinion.
What is the Epstein-Barr connection?
A large study following millions of young adults found that infection with EBV, the glandular fever virus, hugely increased subsequent MS risk, and that MS essentially did not occur in people never infected. The current view is that EBV infection appears necessary but far from sufficient. Since most of the population is infected and very few develop MS, it is a piece of the mechanism rather than a predictor for any individual.
What can I do about the fatigue?
First exclude other causes, since anaemia, thyroid disease, sleep apnoea, depression and medication side effects all contribute and are treatable. Then treat sleep disruption, frequently caused by spasticity, spasms or night-time bladder waking. Then energy management and pacing. And exercise, which counterintuitively reduces fatigue rather than worsening it. Specific medications exist with modest effect. It is the most disabling symptom for most people and the most poorly served.
Why does bladder assessment matter so much?
Because the treatment for an overactive bladder is the opposite of the treatment for incomplete emptying, and giving the wrong one makes things considerably worse. Assessment should include measuring how much urine remains after voiding. Treating this properly also reduces urinary infections, which in turn reduces pseudorelapses. It is extremely common in MS and consistently under-reported through embarrassment.
Do steroids change the long-term course?
No. High-dose steroids speed recovery from a relapse but do not change how complete the eventual recovery is, and they do not affect the long-term course. That is why mild relapses are frequently not treated at all — the drawbacks outweigh a few days of faster recovery in a symptom that will resolve regardless. Rehabilitation after a significant relapse influences the functional endpoint more than steroids do.
Should I avoid exercise?
No, and that older advice was wrong. Exercise improves fatigue, strength, walking, mood and quality of life. Temporary worsening of symptoms during exertion comes from raised body temperature slowing conduction, not from damage, and it resolves on cooling. Cooling strategies before and during activity allow many people to exercise who had concluded they could not.
What happens to MS in pregnancy?
Relapse rate falls during pregnancy, particularly in the third trimester, then rises in the first months after delivery before returning to baseline. That postpartum window is predictable and can be planned for. The main consideration is disease-modifying treatment: some agents must be stopped before conception, some require an interval, and stopping certain ones abruptly causes rebound activity. Plan months in advance rather than after a positive test.
Will I end up in a wheelchair?
Most people with MS never require one, and the picture carried from older accounts is considerably worse than the current reality. Life expectancy is reduced modestly rather than dramatically, and the proportion progressing to secondary progressive disease has fallen since effective treatment became available. The course is highly variable, which means individual predictions are unreliable — a diagnosis is not a prognosis.
📑 Sources and editorial
- McDonald criteria for the diagnosis of multiple sclerosis and subsequent revisions
- NICE guideline on multiple sclerosis in adults
- Bjornevik K et al. — longitudinal analysis of Epstein-Barr virus infection and multiple sclerosis risk
- Evidence on early versus delayed and escalation versus early high-efficacy disease-modifying treatment strategies
- Solomon AJ and colleagues — research on multiple sclerosis misdiagnosis
- Cochrane and systematic reviews of exercise therapy and of fatigue management in multiple sclerosis
- Literature on pregnancy, postpartum relapse risk and disease-modifying therapy planning
- Related reading: muscle spasticity
- Related products: muscle relaxer category
- RXshop Editorial Team — reviewed by James Carter, MD, Neurology
Medical Disclaimer: The information in this article is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek guidance from a qualified healthcare provider with any questions you may have regarding a medical condition, and before starting, stopping or changing any medication.